Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Van Dyke Website

Terry A. Van Dyke, Ph.D.

Selected Publications

1)  Merlino G, Flaherty K, Acquavella N, Day C, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M.
Meeting report: The future of preclinical mouse models in melanoma treatment is now.
Pigment Cell Melanoma Res. [Epub ahead of print], 2013.
2)  Van Dyke T, Merlino G.
Beta-catenin in metastatic melanoma--the smoking gun reloaded.
Pigment Cell Melanoma Res. 25: 125-6, 2012.
3)  Yoon Y, Cowley D, Gallant J, Jones S, Van Dyke T, Rivera-Perez J.
Conditional Aurora A deficiency differentially affects early mouse embryo patterning.
Dev Biol. 371: 77-85, 2012.
4)  Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, McDunn JE, Martin PL, Van Dyke T, Difilippantonio S.
Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.
Cancer Res. 72: 4141-53, 2012.
5)  Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Alshahrour F, Alexander D, Wong K, Van Dyke T.
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Cancer Res. 72: 5921-5933, 2012.
6)  Serber DW, Rogala A, Makarem M, Rosson GB, Simin K, Godfrey V, Van Dyke T, Eaves CJ, Bultman SJ.
The BRG1 chromatin remodeler protects against ovarian cysts, uterine tumors, and mammary tumors in a lineage-specific manner.
PLoS ONE. 7: e31346, 2012.
7)  Lu X, Yang C, Yin C, Van Dyke T, Simin K.
Apoptosis is the essential target of selective pressure against p53, whereas loss of additional p53 functions facilitates carcinoma progression.
Mol. Cancer Res. 9: 430-9, 2011.
8)  Cook DR, Solski PA, Bultman SJ, Kauselmann G, Schoor M, Kuehn R, Friedman LS, Cowley DO, Van Dyke T, Yeh JJ, Johnson L, Der CJ.
The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration.
Genes Cancer. 2: 932-42, 2011.
9)  Van Dyke T.
Finding the tumor copycat: approximating a human cancer.
Nat. Med. 16: 976-7, 2010.
10)  Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.
Genetically engineered mouse models in cancer research.
Adv. Cancer Res. 106: 113-64, 2010.
11)  Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK.
VHL and PTEN loss coordinate to promote mouse liver vascular lesions.
Angiogenesis. 13: 59-69, 2010.
12)  Kuslak SL, Van Dyke T.
Advances in Prostate Cancer Research--AACR Special Conference In Cancer Research.
IDrugs. 12: 159-62, 2009.
13)  Cowley DO, Rivera-Pérez JA, Schliekelman M, He YJ, Oliver TG, Lu L, O'Quinn R, Salmon ED, Magnuson T, Van Dyke T.
Aurora-A kinase is essential for bipolar spindle formation and early development.
Mol. Cell. Biol. 29: 1059-71, 2009.
14)  Schliekelman M, Cowley DO, O'Quinn R, Oliver TG, Lu L, Salmon ED, Van Dyke T.
Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis.
Cancer Res. 69: 45-54, 2009.
15)  Delbove J, Kuwahara Y, Mora-Blanco EL, Godfrey V, Funkhouser WK, Fletcher CD, Van Dyke T, Roberts CW, Weissman BE.
Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.
Mol. Carcinog. 48: 1139-48, 2009.
16)  Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Redmond DE, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ.
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.
Mol. Ther. 16: 1252-60, 2008.
17)  Lu X, Yang C, Hill R, Yin C, Hollander MC, Fornace AJ, Van Dyke T.
Inactivation of gadd45a sensitizes epithelial cancer cells to ionizing radiation in vivo resulting in prolonged survival.
Cancer Res. 68: 3579-83, 2008.
18)  Reilly KM, Van Dyke T.
It takes a (dysfunctional) village to raise a tumor.
Cell. 135: 408-10, 2008.
19)  Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T, Samulski RJ, Monahan PE.
Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose.
Mol. Ther. 16: 280-9, 2008.
20)  Bullitt E, Aylward SR, Van Dyke T, Lin W.
Computer-assisted measurement of vessel shape from 3T magnetic resonance angiography of mouse brain.
Methods. 43: 29-34, 2007.
21)  Johnson CE, Huang YY, Parrish AB, Smith MI, Vaughn AE, Zhang Q, Wright KM, Van Dyke T, Wechsler-Reya RJ, Kornbluth S, Deshmukh M.
Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues.
Proc. Natl. Acad. Sci. U.S.A. 104: 20820-5, 2007.
22)  Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Genome Biol. 8: R76, 2007.
23)  Van Dyke T.
p53 and tumor suppression.
N. Engl. J. Med. 356: 79-81, 2007.
24)  Der CJ, Van Dyke T.
Stopping ras in its tracks.
Cell. 129: 855-7, 2007.
25)  Chai J, Lu X, Godfrey V, Fletcher C, Roberts CW, Van Dyke T, Weissman BE.
Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation.
Cancer Res. 67: 3002-9, 2007.
26)  McLear JA, Garcia-Fresco G, Bhat MA, Van Dyke TA.
In vivo inactivation of pRb, p107 and p130 in murine neuroprogenitor cells leads to major CNS developmental defects and high seizure rates.
Mol. Cell. Neurosci. 33: 260-73, 2006.
27)  Bullitt E, Wolthusen PA, Brubaker L, Lin W, Zeng D, Van Dyke T.
Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice.
AJNR Am J Neuroradiol. 27: 612-9, 2006.
28)  Gutmann DH, Maher EA, Van Dyke T.
Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors.
Cancer Res. 66: 10-3, 2006.
29)  Cowley DO, Muse GW, Van Dyke T.
A dominant interfering Bub1 mutant is insufficient to induce or alter thymic tumorigenesis in vivo, even in a sensitized genetic background.
Mol. Cell. Biol. 25: 7796-802, 2005.
30)  Li C, Bowles DE, van Dyke T, Samulski RJ.
Adeno-associated virus vectors: potential applications for cancer gene therapy.
Cancer Gene Ther. 12: 913-25, 2005.
31)  Van Dyke T.
Cancer biology: sense out of missense.
Nature. 434: 287-8, 2005.
32)  Hill R, Song Y, Cardiff RD, Van Dyke T.
Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
Cancer Res. 65: 10243-54, 2005.
33)  Brubaker LM, Bullitt E, Yin C, Van Dyke T, Lin W.
Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice.
Cancer Res. 65: 8218-23, 2005.
34)  Nistér M, Tang M, Zhang XQ, Yin C, Beeche M, Hu X, Enblad G, van Dyke T, Wahl GM.
p53 must be competent for transcriptional regulation to suppress tumor formation.
Oncogene. 24: 3563-73, 2005.
35)  Hill R, Song Y, Cardiff RD, Van Dyke T.
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.
Cell. 123: 1001-11, 2005.
36)  Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T.
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation.
Cancer Res. 65: 5172-80, 2005.
37)  Albright CD, Salganik RI, Van Dyke T.
Dietary depletion of vitamin E and vitamin A inhibits mammary tumor growth and metastasis in transgenic mice.
J. Nutr. 134: 1139-44, 2004.
38)  Simin K, Wu H, Lu L, Pinkel D, Albertson D, Cardiff RD, Van Dyke T.
pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia.
PLoS Biol. 2: E22, 2004.
39)  Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP.
Pten dose dictates cancer progression in the prostate.
PLoS Biol. 1: E59, 2003.
40)  Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T.
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation.
Cancer Cell. 1: 157-68, 2002.
41)  Van Dyke T, Jacks T.
Cancer modeling in the modern era: progress and challenges.
Cell. 108: 135-44, 2002.
42)  Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, Aldape K.
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.
Oncogene. 21: 7453-63, 2002.
43)  Tolbert D, Lu X, Yin C, Tantama M, Van Dyke T.
p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.
Mol. Cell. Biol. 22: 370-7, 2002.
44)  Perkins EJ, Nair A, Cowley DO, Van Dyke T, Chang Y, Ramsden DA.
Sensing of intermediates in V(D)J recombination by ATM.
Genes Dev. 16: 159-64, 2002.
45)  Lu X, Magrane G, Yin C, Louis DN, Gray J, Van Dyke T.
Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability.
Mol. Cell. Biol. 21: 6017-30, 2001.
46)  Salganik RI, Albright CD, Rodgers J, Kim J, Zeisel SH, Sivashinskiy MS, Van Dyke TA.
Dietary antioxidant depletion: enhancement of tumor apoptosis and inhibition of brain tumor growth in transgenic mice.
Carcinogenesis. 21: 909-14, 2000.
47)  Liao MJ, Yin C, Barlow C, Wynshaw-Boris A, van Dyke T.
Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction.
Mol. Cell. Biol. 19: 3095-102, 1999.
48)  Liao MJ, Van Dyke T.
Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma.
Genes Dev. 13: 1246-50, 1999.
49)  Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, Van Dyke T.
Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors.
Mol. Cell. 2: 283-92, 1998.
50)  Liao MJ, Zhang XX, Hill R, Gao J, Qumsiyeh MB, Nichols W, Van Dyke T.
No requirement for V(D)J recombination in p53-deficient thymic lymphoma.
Mol. Cell. Biol. 18: 3495-501, 1998.
51)  Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T.
Bax suppresses tumorigenesis and stimulates apoptosis in vivo.
Nature. 385: 637-40, 1997.
52)  Li J, Witte DP, Van Dyke T, Askew DS.
Expression of the putative proto-oncogene His-1 in normal and neoplastic tissues.
Am. J. Pathol. 150: 1297-305, 1997.
53)  Patrick TA, Kranz DM, van Dyke TA, Roy EJ.
Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice.
J. Neurooncol. 32: 111-23, 1997.
54)  Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T.
Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration.
Genes Dev. 10: 245-60, 1996.
55)  Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T.
Tissue-specific inactivation of p53 tumor suppression in the mouse.
Genes Dev. 10: 826-35, 1996.
56)  Van Dyke TA.
Analysis of viral-host protein interactions and tumorigenesis in transgenic mice.
Semin. Cancer Biol. 5: 47-60, 1994.
57)  Sáenz Robles MT, Symonds H, Chen J, Van Dyke T.
Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen.
Mol. Cell. Biol. 14: 2686-98, 1994.
58)  Symonds H, Krall L, Remington L, Sáenz Robles M, Jacks T, Van Dyke T.
p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis.
Cold Spring Harb. Symp. Quant. Biol. 59: 247-57, 1994.
59)  Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T.
p53-dependent apoptosis suppresses tumor growth and progression in vivo.
Cell. 78: 703-11, 1994.
60)  Symonds HS, McCarthy SA, Chen J, Pipas JM, Van Dyke T.
Use of transgenic mice reveals cell-specific transformation by a simian virus 40 T-antigen amino-terminal mutant.
Mol. Cell. Biol. 13: 3255-65, 1993.
61)  Chen J, Tobin GJ, Pipas JM, Van Dyke T.
T-antigen mutant activities in vivo: roles of p53 and pRB binding in tumorigenesis of the choroid plexus.
Oncogene. 7: 1167-75, 1992.
62)  Symonds H, Chen JD, Van Dyke T.
Complex formation between the lymphotropic papovavirus large tumor antigen and the tumor suppressor protein p53.
J. Virol. 65: 5417-24, 1991.
63)  Brosnan MJ, Chen LH, Wheeler CE, Van Dyke TA, Koretsky AP.
Phosphocreatine protects ATP from a fructose load in transgenic mouse liver expressing creatine kinase.
Am. J. Physiol. 260: C1191-200, 1991.
64)  Chen JD, Van Dyke T.
Uniform cell-autonomous tumorigenesis of the choroid plexus by papovavirus large T antigens.
Mol. Cell. Biol. 11: 5968-76, 1991.
65)  Brosnan MJ, Chen L, Van Dyke TA, Koretsky AP.
Free ADP levels in transgenic mouse liver expressing creatine kinase. Effects of enzyme activity, phosphagen type, and substrate concentration.
J. Biol. Chem. 265: 20849-55, 1990.
66)  Koretsky AP, Brosnan MJ, Chen LH, Chen JD, Van Dyke T.
NMR detection of creatine kinase expressed in liver of transgenic mice: determination of free ADP levels.
Proc. Natl. Acad. Sci. U.S.A. 87: 3112-6, 1990.
67)  Costa RH, Van Dyke TA, Yan C, Kuo F, Darnell JE.
Similarities in transthyretin gene expression and differences in transcription factors: liver and yolk sac compared to choroid plexus.
Proc. Natl. Acad. Sci. U.S.A. 87: 6589-93, 1990.
68)  Chen JD, Neilson K, Van Dyke T.
Lymphotropic papovavirus early region is specifically regulated transgenic mice and efficiently induces neoplasia.
J. Virol. 63: 2204-14, 1989.
69)  Lübbert H, Hoffman BJ, Snutch TP, van Dyke T, Levine AJ, Hartig PR, Lester HA, Davidson N.
cDNA cloning of a serotonin 5-HT1C receptor by electrophysiological assays of mRNA-injected Xenopus oocytes.
Proc. Natl. Acad. Sci. U.S.A. 84: 4332-6, 1987.
70)  Van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ.
Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice.
J. Virol. 61: 2029-32, 1987.
71)  Yagaloff KA, Lozano G, van Dyke T, Levine AJ, Hartig PR.
Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice.
Brain Res. 385: 389-94, 1986.
72)  Van Dyke T, Finlay C, Levine AJ.
A comparison of several lines of transgenic mice containing the SV40 early genes.
Cold Spring Harb. Symp. Quant. Biol. 50: 671-8, 1985.
73)  Brinster RL, Chen HY, Messing A, van Dyke T, Levine AJ, Palmiter RD.
Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors.
Cell. 37: 367-79, 1984.
74)  Van Dyke TA, Rickles RJ, Flanegan JB.
Genome-length copies of poliovirion RNA are synthesized in vitro by the poliovirus RNA-dependent RNA polymerase.
J. Biol. Chem. 257: 4610-7, 1982.
75)  Sierra F, Leza A, Marashi F, Plumb M, Rickles R, Van Dyke T, Clark S, Wells J, Stein GS, Stein JL.
Human histone genes are interspersed with members of the Alu family and with other transcribed sequences.
Biochem. Biophys. Res. Commun. 104: 785-92, 1982.
76)  Sierra F, Lichtler A, Marashi F, Rickles R, Van Dyke T, Clark S, Wells J, Stein G, Stein J.
Organization of human histone genes.
Proc. Natl. Acad. Sci. U.S.A. 79: 1795-9, 1982.
77)  Van Dyke TA, Flanegan JB.
Identification of poliovirus polypeptide P63 as a soluble RNA-dependent RNA polymerase.
J. Virol. 35: 732-40, 1980.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/2/2013.